February 22nd 2015, 8:00am – 6:30pm | 401 Terry Avenue North, Seattle, WA 98109

Agenda

08:00-08:45 Registration and Breakfast

08:45-09:00 Welcome and objectives of the meeting
Victor Rydgren (GAFFI, Switzerland) and Jennifer Dent (BIO Ventures for Global Health-BVGH, USA)

09:00-09:30 Fungal infections: The key to improving AIDS and TB outcomes
David Denning (GAFFI, Switzerland; University of Manchester, UK)

09:30-10:15 Panel Session 1: Fungal infection diagnosis in HIV/AIDS patients
Introduction and moderator: Arnaldo Colombo (Federal University of São Paulo, Brazil)

Panelists: Tom Chiller (Centers for Disease Control-CDC, USA)
David Boulware (University of Minnesota, USA)
Beatriz Gomez (Universidad del Rosario, Colombia)
Blanca Samayoa (Asociación de Salud Integral Guatemala)
Carlos Fritzsche (University of Rostock Medical School, Germany)

10:15-10:45 Coffee

10:45-11:00 Review of national fungal disease surveillance programs
Arunaloke Chakrabarti (Postgraduate Institute of Medical Education & Research, India)

11:00-11:45 Panel Session 2: Antifungals for fungal infections in HIV/AIDS patients
Introduction and moderator: Peter Pappas (University of Alabama, USA)

Panelists: Juan Luis Rodriguez Tudela (GAFFI, Switzerland; University of Manchester, UK)
Lenias Hwenda (Medicines for Africa, Switzerland)
Andrew Kambugu (Infectious Disease Institute-IDI, Uganda)
Jonathan Kaplan (CDC, USA)

11:45-12:15 Briefing Session: Commercial opportunities and sustainability

New diagnostics opportunities: products, strategies, and markets
Malcolm Richardson (Mycology Reference Centre, University of Manchester, UK; International Society for Human and Animal Mycology-ISHAM)

New antifungals: what do we need?
Tom Patterson (San Antonio Center for Medical Mycology, University of Texas Health Science Center at San Antonio, USA)

12:15-13:15 Lunch break
13:15-14:15  **Gap analysis: drugs and diagnostics for HIV/AIDS fungal co-infections**
Peter Godfrey-Faussett *(UNAIDS, Switzerland; London School of Hygiene and Tropical Medicine, UK)*

**Open discussion**
Led by Ade Fakoya *(The Global Fund, Switzerland)*

14:15- 15:00  **Panel Session 3: TB that is not TB: Chronic Pulmonary Aspergillosis (CPA)**

**Introduction and moderator:** Haileyesus Getahun *(WHO, Switzerland)*

**Panelists:**
- Gilla Kaplan *(Bill & Melinda Gates Foundation, USA)*
- Iain Page *(University of Manchester, UK)*
- Arunaloke Chakrabarti *(Postgraduate Institute of Medical Education & Research, India)*
- Jeremiah Chakaya *(Kenya Association for the Prevention of Tuberculosis and Lung Disease-KAPTLD, Kenya)*

15:00-15:30  **Coffee**

15:30-16:15  **Keynote presentation: Conquering AIDS and TB, reducing deaths**
Douglas Shaffer *(Chief Medical Officer, Office of the Global AIDS Coordinator, United States Department of State)*

16:30-18:00  **Round table: ‘Getting to Zero - HIV-related deaths’**

**Moderators:** David Denning and David Perlin *(PHRI, New Jersey Medical School-Rutgers, USA)*

Participants will identify action points for the development of a ten-year road map to reduce deaths globally due to fungal infections.

**Participants:**
- William Powderly *(Washington University, St. Louis, USA)*
- Glenda Gray *(South African Medical Research Council, South Africa)*
- Ellis Owusu-Dabo *(Kwame Nkrumah University of Science & Technology-KNUT; Kumasi Centre for Collaborative Research into Tropical Medicine-KCCR, Ghana)*
- John T. Brooks *(CDC, USA)*
- Meg Doherty *(WHO, Switzerland)*

**Topics for discussion**
1. What guidelines are needed?
2. What epidemiological data is needed?
3. What are the challenges to sustainable supply of antifungals and access at affordable prices?
4. What should GAFFI be doing to facilitate access to drugs and diagnostics in developing world?
5. What capacity building is needed?

18:00-18:15  **Closing remarks and final thoughts**
*David Denning (GAFFI, Switzerland; University of Manchester, UK)*

Note: There will be a closed follow-up session on February 23rd (by invitation) to consolidate ideas and inputs from the meeting.